On Friday, Schrodinger stock earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 73.
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the top-performing stocks tend to have an 80 or better RS Rating as they begin their biggest price moves. See if Schrodinger stock can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Is Schrodinger Stock A Buy?
Schrodinger stock has climbed more than 5% past a 23.65 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the medical stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
The New York-based medical company reported 0% EPS growth in the latest quarterly report. Sales rose -17%. The company is expected to report its latest numbers on or around Feb. 26.
Schrodinger stock earns the No. 19 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
